5 Biotech Stocks to Buy Today According to Ken Fisher

4. Roche Holding AG (OTCMKTS:RHHBY)

Fisher Asset Management’s Stake Value: $242 million

Percentage of Fisher Asset Management’s 13F Portfolio: 0.13%

Number of Hedge Fund Holders: 3

Roche Holding AG (OTCMKTS:RHHBY) is a Swiss company that develops and sells prescription pharmaceuticals and diagnostics. It describes itself as the world’s largest biotechnology company, through having developed treatments for a variety of diseases such as those covering cancer, the eyes, immune system, and the nervous system.

For its latest fiscal year, Roche Holding AG (OTCMKTS:RHHBY) posted CHF62 billion in revenue and CHF19.81 in non-GAAP EPS, beating analyst revenue estimates and missing those for non-GAAP EPS. Stifel set a CHF410 price target for the company in February 2022, stating that the company’s COVID-19 diagnostics kit was a testament to its transformative capabilities.

Mr. Fisher’s investment firm owned 4.6 million Roche Holding AG (OTCMKTS:RHHBY) shares worth $242 million as December 2021 came to an end. Insider Monkey studied the holdings of 924 hedge funds for Q4 2021 and discovered that 3 had owned the company’s shares.

Harding Loevner mentioned the company in its Q4 2021 investor letter, stating that:

“Health Care boosted relative performance as our holdings benefitted from the pandemic both coming and going. Roche and Lonza saw heightened interest in treatment, testing, and vaccination activities to battle the waves of newer COVID-19 variants.